53 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
RGNX REGENXBIO Inc. $70.3974 $2.27B N/A
Article Searches
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4327577-regenxbio-inc-rgnx-ceo-kenneth-mills-on-q4-2019-results-earnings-call-transcript?source=feed_sector_healthcare Feb 26, 2020 - REGENXBIO, Inc. (NASDAQ:RGNX) Q4 2019 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President
Regenxbio Inc. (RGNX) Q4 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/02/26/regenxbio-inc-rgnx-q4-2019-earnings-call-transcrip.aspx?source=iedfolrf0000001 Feb 26, 2020 - RGNX earnings call for the period ending December 31, 2019.
Applied Genetic Stock Up on Favorable Eye Therapy Study Data http://www.zacks.com/stock/news/711529/applied-genetic-stock-up-on-favorable-eye-therapy-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-711529 Jan 10, 2020 - Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.
SWN, RGNX and CYTK among notable after hours movers https://seekingalpha.com/news/3526304-swn-rgnx-and-cytk-among-notable-after-hours-movers?utm_source=feed_news_all&utm_medium=referral Dec 13, 2019 - Gainers: GVA +4.8%. CYTK +3.3%. TEN +3.1%. BRFS +2.1%. SWN +2%.Losers: AUDC -3.8%.  CX -2.6%. NK -1.4%. RGNX -1%.
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4302900-regenxbio-inc-rgnx-ceo-kenneth-mills-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare Nov 05, 2019 - REGENXBIO, Inc. (NASDAQ:RGNX) Q3 2019 Earnings Conference Call November 5, 2019 04:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President
Regenxbio Inc. (RGNX) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/11/05/regenxbio-inc-rgnx-q3-2019-earnings-call-transcrip.aspx?source=iedfolrf0000001 Nov 05, 2019 - RGNX earnings call for the period ending September 30, 2019.
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates http://www.zacks.com/stock/news/605253/regenxbio-rgnx-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-605253 Nov 05, 2019 - Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA http://www.zacks.com/stock/news/565788/ultragenyxs-rare-nda-for-lc-faod-drug-accepted-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-565788 Oct 15, 2019 - Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
Big Pharma Has Mad Love For These 2 Biotechs https://www.fool.com/investing/2019/10/11/big-pharma-has-mad-love-for-these-2-biotechs.aspx?source=iedfolrf0000001 Oct 11, 2019 - These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.
Wet AMD Space in Focus: New Drug Approvals & Key Advancements http://www.zacks.com/stock/news/557772/wet-amd-space-in-focus-new-drug-approvals-key-advancements?cid=CS-ZC-FT-analyst_blog|industry_focus-557772 Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

Pages: 123456

Page 1>